Top Markets
Coin of the day
MegaPro Biomedical Co., Ltd MegaPro Biomedical Co., Ltd

MegaPro Biomedical Co., Ltd

6827
Rangering i aksjer #28596
MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily... MegaPro Biomedical Co., Ltd. operates as a biotechnology enterprise primarily focused on pioneering nanodrugs. Its innovative development pipeline includes MPB-1523, an IOP injection currently in Phase II clinical evaluation for addressing hepatocellular carcinoma. Simultaneously, MPB-1514, an iron injection, is also undergoing Phase II clinical trials, targeting iron deficiency anemia. Furthermore, the firm is advancing MPB-1734, an anti-cancer pharmaceutical, which is in preclinical assessment for the treatment of malignant tumors. Established in 2014, this company is headquartered in Zhubei, Taiwan.
Aksjekurs
$0.32276013
Sist synkronisert: 2026-08-17
Markedsverdi
$25.60M
Endring (1 dag)
0.00%
Endring (1 år)
-38.97%
Land
TW
Handel MegaPro Biomedical Co., Ltd (6827)

Kategori

P/S-forhold for MegaPro Biomedical Co., Ltd (6827)
P/S-forhold per 2026 TTM: 0
Ifølge MegaPro Biomedical Co., Ltd sine siste finansielle rapporter og aksjekurs er selskapets nåværende P/S-forhold (TTM) 0. Ved slutten av 2026 hadde selskapet et P/S-forhold på 0.
P/S-historikk for MegaPro Biomedical Co., Ltd fra 2026 til 2026
P/S-forhold ved hvert års slutt
År P/S-forhold Endre
Ikke nok data for de angitte datoene.
P/S-forhold for lignende selskaper eller konkurrenter
Selskap P/S-forhold Forskjell i P/S-forhold Land
10.17 -
US
11.28 -
US
10.13 -
NL
2.95 -
AU
- -
CH